Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application
By Christopher Kuo
Aardvark Therapeutics shares plunged after the Food and Drug Administration placed a full clinical hold on the company's investigational new-drug application for ARD-101, Aardvark's treatment for a rare genetic disorder characterized by insatiable hunger, Prader-Willi syndrome.
Shares of the biopharmaceutical company fell 23% on Friday to $5.18. The company's shares are down 61% year to date.
The FDA's clinical hold applies to all ongoing clinical studies under the NDA, including the Phase 3 Hero trial, Aardvark said. The company is in talks with the FDA to try to resolve the hold and determine a path forward for the ARD-101 program, the company said.
In February, Aardvark had voluntarily paused its Phase 3 Hero trial and open-label extension trials evaluating ARD-101. The pause came after the company saw unexpected reversible cardiac observations in a separate healthy-volunteer trial, the company said.
Aardvark plans to unblind the clinical data from these trials. As of Feb. 27, it had dosed 68 patients in the randomized controlled Hero trial and 19 patients in the Ole trial, it said.
Write to Christopher Kuo at chris.kuo@wsj.com
(END) Dow Jones Newswires
May 15, 2026 10:55 ET (14:55 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
These Overvalued Stocks Have Plenty of Room to Fall
3 of the Best Dividend Stocks to Own
4 Big Impacts from the US Midterm Elections for Investors
3 Stocks to Sell and 3 Stocks to Buy for November
United States